Literature DB >> 19544052

Subacute exposure to N-ethyl perfluorooctanesulfonamidoethanol results in the formation of perfluorooctanesulfonate and alters superoxide dismutase activity in female rats.

Wei Xie1, Qian Wu, Izabela Kania-Korwel, Job C Tharappel, Sanjay Telu, Mitchell C Coleman, Howard P Glauert, Kurunthachalam Kannan, S V S Mariappan, Douglas R Spitz, Jamie Weydert, Hans-Joachim Lehmler.   

Abstract

Perfluorooctanesulfonamides, such as N-ethyl perfluorooctanesulfonamidoethanol (N-EtFOSE), are large scale industrial chemicals but their disposition and toxicity are poorly understood despite significant human exposure. The hypothesis that subacute exposure to N-EtFOSE, a weak peroxisome proliferator, causes a redox imbalance in vivo was tested using the known peroxisome proliferator, ciprofibrate, as a positive control. Female Sprague-Dawley rats were treated orally with N-EtFOSE, ciprofibrate or corn oil (vehicle) for 21 days, and levels of N-EtFOSE and its metabolites as well as markers of peroxisome proliferation and oxidative stress were assessed in serum, liver and/or uterus. The N-EtFOSE metabolite profile in liver and serum was in good agreement with reported in vitro biotransformation pathways in rats and the metabolite levels decreasing in the order perfluorooctanesulfonate >> perfluorooctanesulfonamide ~ N-ethyl perfluorooctanesulfonamidoacetate >> perfluorooctanesulfonamidoethanol approximately N-EtFOSE. Although N-EtFOSE treatment significantly decreased the growth rate, increased relative liver weight and activity of superoxide dismutases (SOD) in liver and uterus (total SOD, CuZnSOD and MnSOD), a metabolic study revealed no differences in the metabolome in serum from N-EtFOSE-treated and control animals. Ciprofibrate treatment increased liver weight and peroxisomal acyl Co-A oxidase activity in the liver and altered antioxidant enzyme activities in the uterus and liver. According to NMR metabolomic studies, ciprofibrate treated animals had altered serum lipid profiles compared to N-EtFOSE-treated and control animals, whereas putative markers of peroxisome proliferation in serum were not affected. Overall, this study demonstrates the biotransformation of N-EtFOSE to PFOS in rats that is accompanied by N-EtFOSE-induced alterations in antioxidant enzyme activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19544052      PMCID: PMC2755535          DOI: 10.1007/s00204-009-0450-y

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  81 in total

Review 1.  Metabonomics: a platform for studying drug toxicity and gene function.

Authors:  Jeremy K Nicholson; John Connelly; John C Lindon; Elaine Holmes
Journal:  Nat Rev Drug Discov       Date:  2002-02       Impact factor: 84.694

2.  Use of newborn screening program blood spots for exposure assessment: declining levels of perluorinated compounds in New York State infants.

Authors:  Henry M Spliethoff; Lin Tao; Shannon M Shaver; Kenneth M Aldous; Kenneth A Pass; Kurunthachalam Kannan; George A Eadon
Journal:  Environ Sci Technol       Date:  2008-07-15       Impact factor: 9.028

3.  Mitochondrial permeability transition as the critical target of N-acetyl perfluorooctane sulfonamide toxicity in vitro.

Authors:  Timothy M O'Brien; Kendall B Wallace
Journal:  Toxicol Sci       Date:  2004-08-13       Impact factor: 4.849

4.  Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid.

Authors:  M W Wilson; L T Lay; C K Chow; H H Tai; L W Robertson; H P Glauert
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

5.  Further studies on the involvement of selenium in peroxisome proliferation in rat liver. Comparison of effects with clofibric acid and perfluorooctanoic acid and the pharmacokinetics of [14C]clofibrate.

Authors:  U Olsson; C Sundberg; K Andersson; J W De Pierre
Journal:  Biochem Pharmacol       Date:  1993-11-17       Impact factor: 5.858

6.  Perfluorooctane sulfonic acid is a potent inducer of peroxisomal fatty acid beta-oxidation and other activities known to be affected by peroxisome proliferators in mouse liver.

Authors:  A K Sohlenius; A M Eriksson; C Högström; M Kimland; J W DePierre
Journal:  Pharmacol Toxicol       Date:  1993-02

7.  Immunotoxic changes associated with a 7-day oral exposure to perfluorooctanesulfonate (PFOS) in adult male C57BL/6 mice.

Authors:  Li Zheng; Guang-Hui Dong; Yi-He Jin; Qin-Cheng He
Journal:  Arch Toxicol       Date:  2008-10-21       Impact factor: 5.153

8.  Potentiating hypergastrinemic effect by the peroxisome proliferator ciprofibrate and omeprazole in the rat.

Authors:  T A Hammer; A K Sandvik; H L Waldum
Journal:  Scand J Gastroenterol       Date:  1998-06       Impact factor: 2.423

9.  Perfluorooctanesulfonate and other fluorochemicals in the serum of American Red Cross adult blood donors.

Authors:  Geary W Olsen; Timothy R Church; John P Miller; Jean M Burris; Kristen J Hansen; James K Lundberg; John B Armitage; Ross M Herron; Zahra Medhdizadehkashi; John B Nobiletti; E Mary O'Neill; Jeffrey H Mandel; Larry R Zobel
Journal:  Environ Health Perspect       Date:  2003-12       Impact factor: 9.031

10.  Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000.

Authors:  Antonia M Calafat; Lee-Yang Wong; Zsuzsanna Kuklenyik; John A Reidy; Larry L Needham
Journal:  Environ Health Perspect       Date:  2007-11       Impact factor: 9.031

View more
  5 in total

1.  Model and cell membrane partitioning of perfluorooctanesulfonate is independent of the lipid chain length.

Authors:  Wei Xie; Gabriele Ludewig; Kai Wang; Hans-Joachim Lehmler
Journal:  Colloids Surf B Biointerfaces       Date:  2009-10-27       Impact factor: 5.268

2.  Disruption of phosphatidylcholine monolayers and bilayers by perfluorobutane sulfonate.

Authors:  E Davis Oldham; Wei Xie; Amir M Farnoud; Jennifer Fiegel; Hans-Joachim Lehmler
Journal:  J Phys Chem B       Date:  2012-08-13       Impact factor: 2.991

3.  Targeted overexpression of mitochondrial catalase prevents radiation-induced cognitive dysfunction.

Authors:  Vipan K Parihar; Barrett D Allen; Katherine K Tran; Nicole N Chmielewski; Brianna M Craver; Vahan Martirosian; Josh M Morganti; Susanna Rosi; Roman Vlkolinsky; Munjal M Acharya; Gregory A Nelson; Antiño R Allen; Charles L Limoli
Journal:  Antioxid Redox Signal       Date:  2015-01-01       Impact factor: 8.401

Review 4.  Perfluoroalkyl and polyfluoroalkyl substances in the environment: terminology, classification, and origins.

Authors:  Robert C Buck; James Franklin; Urs Berger; Jason M Conder; Ian T Cousins; Pim de Voogt; Allan Astrup Jensen; Kurunthachalam Kannan; Scott A Mabury; Stefan P J van Leeuwen
Journal:  Integr Environ Assess Manag       Date:  2011-10       Impact factor: 2.992

5.  Internal Relative Potency Factors for the Risk Assessment of Mixtures of Per- and Polyfluoroalkyl Substances (PFAS) in Human Biomonitoring.

Authors:  Wieneke Bil; Marco J Zeilmaker; Bas G H Bokkers
Journal:  Environ Health Perspect       Date:  2022-07-26       Impact factor: 11.035

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.